Related Experiment Video
Updated: Feb 10, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
The era of ErbB-receptor-targeted therapies: advances toward personalized medicine
Sarah Bacus1,2,3, Neil L Spector1,2,3, Yosef Yarden1,2,3
1Targeted Molecular Diagnostics LLC, 610 Oakmont Lane, Westmont, IL 6055, USA. sbacus@tmdlab.com.
Abstract:
Central themes in medical practice are the diagnosis, prognosis and treatment of disease. Advances have been made in a number of malignanices including breast cancer, where new therapeutic strategies have significantly improved response rates, the disease-free interval and overall survival. However, complete responses to chemotherapy are achieved in only 10-20% of patients. Recent advances in the understanding of the cellular and molecular biology of cancer have led to the identification of oncogenes and tumor suppressor genes that influence the rate of tumor cell proliferation and cancer progression. These oncogenes represent important therapeutic targets and are currently being incorporated into the design of novel therapeutic approaches. This review emphasizes the role of the ErbB oncogenic receptor family, its effect on tumor biologic behavior and its role as a target for various therapeutic regimens.
Insights
This review highlights advances in cancer treatment, focusing on the ErbB oncogenic receptor family. Targeting these receptors offers new therapeutic strategies for improved patient outcomes in malignancies like breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Medical Therapeutics
Background:
- Medical practice focuses on disease diagnosis, prognosis, and treatment.
- Advances in breast cancer therapy have improved outcomes, but complete chemotherapy response remains limited (10-20%).
- Understanding cancer's cellular and molecular biology has identified oncogenes and tumor suppressor genes crucial for tumor growth and progression.
Purpose of the Study:
- To review the role of the ErbB oncogenic receptor family in cancer.
- To discuss the impact of ErbB receptors on tumor biologic behavior.
- To highlight ErbB receptors as therapeutic targets for novel treatment strategies.
Main Methods:
- Literature review of recent advances in cancer biology and therapeutics.
- Focus on oncogenic receptor families, specifically ErbB.
- Analysis of therapeutic regimens targeting ErbB receptors.
Main Results:
- The ErbB oncogenic receptor family significantly influences tumor cell proliferation and cancer progression.
- Identification of ErbB receptors as key targets for novel therapeutic approaches.
- New therapeutic strategies targeting ErbB have shown promise in improving treatment response.
Conclusions:
- The ErbB oncogenic receptor family is a critical target for developing advanced cancer therapies.
- Targeted therapies against ErbB receptors represent a promising direction for improving patient survival and disease-free intervals.
- Further research into ErbB-targeted regimens is essential for optimizing cancer treatment.
More Related Videos
06:42Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications
Published on: September 2, 2025
12:38Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
Published on: July 19, 2007
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Gene Therapy
Internal Receptors
Microorganisms in Medicine and Therapeutics
Personal Identity